Eli Lilly's Q3 Revenue Soars 54%, Net Income Jumps 475%

Ticker: LLY · Form: 10-Q · Filed: 2025-10-30T00:00:00.000Z

Sentiment: bullish

Topics: Pharmaceuticals, Biotechnology, Earnings Growth, R&D Investment, Healthcare, Large Cap, Innovation

Related Tickers: LLY, PFE, MRK, JNJ, AMGN

TL;DR

**LLY is absolutely crushing it, buy the dip if you can find one, this growth is unsustainable for competitors.**

AI Summary

Eli Lilly and Company (LLY) reported a robust financial performance for the quarter ended September 30, 2025, with revenue surging to $17,600.8 million, a significant increase from $11,439.1 million in the same period of 2024. This 53.8% year-over-year growth was primarily driven by net product revenue, which rose to $16,330.5 million from $10,571.6 million. Net income dramatically increased to $5,582.5 million, up from $970.3 million in Q3 2024, representing a 475.3% jump. Diluted earnings per share also saw a substantial rise to $6.21 from $1.07. Key business changes include increased investments in research and development, which grew to $3,465.7 million from $2,734.1 million, and a notable increase in prepaid expenses to $20,248.7 million from $8,340.5 million at year-end 2024. Risks highlighted include the significant costs and uncertainties in pharmaceutical R&D, intense competition, and the impact of global macroeconomic conditions. The strategic outlook appears positive, supported by strong revenue growth and increased R&D spending, indicating continued investment in pipeline development.

Why It Matters

Eli Lilly's explosive growth in revenue and net income signals strong market demand for its pharmaceutical products, likely driven by recent drug launches or increased adoption of existing therapies. For investors, this performance could reinforce confidence in LLY's growth trajectory and pipeline, potentially leading to continued stock appreciation. Employees may see enhanced job security and opportunities within a thriving company, while customers could benefit from continued innovation and access to new treatments. In the competitive pharmaceutical landscape, LLY's substantial R&D investment and market penetration could put pressure on rivals like Pfizer and Merck, forcing them to accelerate their own development efforts to keep pace.

Risk Assessment

Risk Level: medium — While Eli Lilly shows strong financial performance, the 'Acquired in-process research and development' expense for the nine months ended September 30, 2025, was $2,381.2 million, indicating significant reliance on external innovation which carries inherent integration and success risks. Additionally, the company's 'Prepaid expenses' surged to $20,248.7 million from $8,340.5 million at December 31, 2024, suggesting substantial upfront commitments that could tie up capital if not effectively utilized. The filing also explicitly mentions 'significant costs and uncertainties in the pharmaceutical research and development process' and 'intense competition' as key risk factors.

Analyst Insight

Investors should consider holding or increasing their position in LLY, given the exceptional revenue and net income growth. Monitor the effectiveness of the substantial R&D investments and acquired in-process R&D, as these are critical for sustaining long-term growth and pipeline success. Pay close attention to future product launches and market uptake to ensure the company maintains its competitive edge.

Financial Highlights

debt To Equity
N/A
revenue
$17,600.8M
operating Margin
N/A
total Assets
$114,935.4M
total Debt
N/A
net Income
$5,582.5M
eps
$6.21
gross Margin
N/A
cash Position
$9,791.9M
revenue Growth
+53.8%

Revenue Breakdown

SegmentRevenueGrowth
Net Product Revenue$16,330.5M+53.8%

Key Numbers

Key Players & Entities

FAQ

What were Eli Lilly's key financial highlights for Q3 2025?

Eli Lilly's revenue for Q3 2025 was $17,600.8 million, a 53.8% increase from $11,439.1 million in Q3 2024. Net income surged to $5,582.5 million, up 475.3% from $970.3 million in the prior year, with diluted EPS reaching $6.21.

How did Eli Lilly's research and development spending change in Q3 2025?

Research and development expenses for Eli Lilly increased to $3,465.7 million in Q3 2025, up from $2,734.1 million in Q3 2024. For the nine months ended September 30, 2025, R&D was $9,535.5 million, compared to $7,968.1 million in the same period of 2024.

What is the significance of Eli Lilly's increased prepaid expenses?

Eli Lilly's prepaid expenses significantly increased to $20,248.7 million as of September 30, 2025, from $8,340.5 million at December 31, 2024. This substantial increase suggests significant upfront investments or commitments, potentially related to future R&D, manufacturing, or strategic partnerships.

What are the primary risks Eli Lilly faces according to the 10-Q filing?

The 10-Q highlights several risks for Eli Lilly, including significant costs and uncertainties in pharmaceutical R&D, intense competition, market uptake challenges for launched products, continued pricing pressures, and the impact of global macroeconomic conditions.

How much cash did Eli Lilly generate from operating activities?

For the nine months ended September 30, 2025, Eli Lilly generated $13,588.4 million in net cash from operating activities, a substantial increase from $6,344.1 million in the same period of 2024.

What was Eli Lilly's total equity as of September 30, 2025?

Eli Lilly's total equity as of September 30, 2025, was $23,850.8 million, a significant increase from $14,271.6 million at December 31, 2024.

Did Eli Lilly engage in any share repurchase programs?

Yes, as of September 30, 2025, Eli Lilly had $12.40 billion remaining under its $15.00 billion share repurchase program authorized in December 2024. The company purchased $2,600.3 million of common stock during the nine months ended September 30, 2025.

What was the change in Eli Lilly's total assets?

Eli Lilly's total assets increased to $114,935.4 million as of September 30, 2025, from $78,714.9 million at December 31, 2024, reflecting significant growth in current assets, property and equipment, and deferred tax assets.

How much did Eli Lilly spend on acquisitions in Q3 2025?

For the nine months ended September 30, 2025, Eli Lilly paid $549.4 million in cash for acquisitions, net of cash acquired. Additionally, $2,584.3 million was spent on purchases of in-process research and development.

What is Eli Lilly's outlook on new accounting standards?

Eli Lilly intends to adopt ASU 2023-09 (Income Taxes) in its Annual Report on Form 10-K for the year ending December 31, 2025, and ASU 2024-03 (Expense Disaggregation) in its Annual Report on Form 10-K for the year ending December 31, 2027. The company is currently evaluating the potential impact of these standards on its disclosures.

Risk Factors

Industry Context

Eli Lilly operates in the highly competitive pharmaceutical sector, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Key trends include a focus on innovative therapies for chronic diseases, advancements in biologics, and increasing demand for personalized medicine. The industry faces ongoing pricing pressures and patent expirations, necessitating continuous pipeline development and strategic partnerships.

Regulatory Implications

The pharmaceutical industry is heavily regulated by bodies like the FDA. Changes in regulatory requirements, approval processes, or post-market surveillance can significantly impact product launches, market access, and ongoing sales. Lilly's substantial R&D spending suggests a focus on innovation, which is subject to rigorous clinical trial and approval standards.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Acquired in-process research and development
Costs associated with research and development projects acquired from other companies, often expensed immediately if certain criteria are not met. (A significant expense item ($655.7M in Q3 2025), indicating strategic acquisitions or licensing of R&D assets.)
Other comprehensive income
Unrealized gains or losses on investments, foreign currency translation adjustments, and pension plan adjustments that are not included in net income. (Contributed to a substantial increase in comprehensive income ($509.7M in Q3 2025), boosting overall equity.)
Prepaid expenses
Payments made in advance for goods or services that will be consumed or used in the future. (A dramatic increase to $20,248.7M highlights significant upfront commitments or investments.)
Diluted earnings per share
Net income divided by the total number of diluted common shares outstanding, including the effect of stock options and convertible securities. (A key profitability metric for shareholders, showing a significant rise to $6.21 in Q3 2025.)

Year-Over-Year Comparison

Compared to the prior year's comparable period (Q3 2024), Eli Lilly has demonstrated exceptional financial performance. Revenue surged by 53.8% to $17,600.8 million, primarily driven by net product sales. Net income saw a dramatic increase of 475.3% to $5,582.5 million, leading to a substantial rise in diluted EPS from $1.07 to $6.21. While R&D investment also increased, the company's balance sheet shows a significant build-up in prepaid expenses and inventories, alongside a much stronger cash position.

Filing Stats: 4,478 words · 18 min read · ~15 pages · Grade level 7.4 · Accepted 2025-10-30 11:15:28

Filing Documents

Financial Information

PART I. Financial Information 5 Item 1.

Financial Statements

Financial Statements 5 Consolidated Condensed Statements of Operations 5 Consolidated Condensed Statements of Comprehensive Income 6 Consolidated Condensed Balance Sheets 7 Consolidated Condensed Statements of Shareholders' Equity 8 Consolidated Condensed Statements of Cash Flows 10 Notes to Consolidated Condensed Financial Statements 11 Item 2.

Management's Discussion and Analysis of Results of Operations and Financial Condition

Management's Discussion and Analysis of Results of Operations and Financial Condition 34 Executive Overview 34 Results of Operations 38 Financial Condition and Liquidity 41 Critical Accounting Estimates 42 Available Information on our Website 42 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 43 Item 4.

Controls and Procedures

Controls and Procedures 43

Other Information

PART II. Other Information 44 Item 1.

Legal Proceedings

Legal Proceedings 44 Item 1A.

Risk Factors

Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 5. Other Information 44 Item 6. Exhibits 45

Signatures

Signatures 45 2

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as "may," "could," "aim," "seek," "believe," "will," "expect," "project," "estimate," "intend," "target," "anticipate," "plan," "continue," or similar expressions or future or conditional verbs. Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements. Forward-looking statements are based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated: the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; the impact and uncertain outcome of acquisitions and business development transactions and related costs; intense competition affecting our products, pipeline, or industry; market uptake of launched products and indications; continued pricing pressures and the impact of actions of governmental and private actors affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations re

Financial Information

PART I. Financial Information

Financial Statements

Item 1. Financial Statements Consolidated Condensed Statements of Operations (Unaudited) ELI LILLY AND COMPANY (Dollars and shares in millions, except per-share data) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue (Note 2) $ 17,600.8 $ 11,439.1 $ 45,887.0 $ 31,509.9 Costs, expenses, and other: Cost of sales 3,008.3 2,170.8 7,680.3 6,014.5 Research and development 3,465.7 2,734.1 9,535.5 7,968.1 Marketing, selling, and administrative 2,740.7 2,099.8 7,962.6 6,169.3 Acquired in-process research and development (Note 3) 655.7 2,826.4 2,381.2 3,091.2 Asset impairment, restructuring, and other special charges (Note 5) 364.9 81.6 399.9 516.6 Other–net, (income) expense (Note 12) 133.1 ( 62.0 ) 462.7 108.5 10,368.4 9,850.7 28,422.2 23,868.2 Income before income taxes 7,232.4 1,588.4 17,464.8 7,641.7 Income taxes (Note 8) 1,649.9 618.1 3,462.5 1,461.5 Net income $ 5,582.5 $ 970.3 $ 14,002.3 $ 6,180.2 Earnings per share: Basic $ 6.22 $ 1.08 $ 15.60 $ 6.86 Diluted $ 6.21 $ 1.07 $ 15.56 $ 6.83 Shares used in calculation of earnings per share: Basic 896.9 901.0 897.8 900.9 Diluted 898.8 905.0 899.7 904.4 See notes to consolidated condensed financial statements. 5 Consolidated Condensed Statements of Comprehensive Income (Unaudited) ELI LILLY AND COMPANY (Dollars in millions) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net income $ 5,582.5 $ 970.3 $ 14,002.3 $ 6,180.2 Other comprehensive income, net of tax (Note 11) 509.7 103.7 1,115.6 52.2 Comprehensive income $ 6,092.2 $ 1,074.0 $ 15,117.9 $ 6,232.4 See notes to consolidated condensed financial statements. 6 Consolidated Condensed Balance Sheets ELI LILLY AND COMPANY (Dollars in millions) September 30, 2025 December 31, 2024 Assets (Unaudited) Current Assets Cash and cash equivalents (Note 7) $ 9,791.9 $ 3,268.4 Short-term investments (Note 7) 121.6 154.8 Accounts receivable, net of

View on Read The Filing